ASCO GI: Data from Adjuvant CRC Study Perplexing

SAN FRANCISCO (MedPage Today) — Activity in advanced colorectal cancer failed to translate into a survival benefit in the adjuvant setting for bevacizumab (Avastin), results of a large European trial showed.

Post a Comment

Comments are closed.